1. Home
  2. PPBT vs FRSX Comparison

PPBT vs FRSX Comparison

Compare PPBT & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PPBT
  • FRSX
  • Stock Information
  • Founded
  • PPBT 2010
  • FRSX N/A
  • Country
  • PPBT Israel
  • FRSX Israel
  • Employees
  • PPBT N/A
  • FRSX N/A
  • Industry
  • PPBT Biotechnology: Pharmaceutical Preparations
  • FRSX Computer Software: Prepackaged Software
  • Sector
  • PPBT Health Care
  • FRSX Technology
  • Exchange
  • PPBT Nasdaq
  • FRSX Nasdaq
  • Market Cap
  • PPBT 7.4M
  • FRSX 7.7M
  • IPO Year
  • PPBT N/A
  • FRSX 2017
  • Fundamental
  • Price
  • PPBT $0.71
  • FRSX $2.20
  • Analyst Decision
  • PPBT Strong Buy
  • FRSX
  • Analyst Count
  • PPBT 1
  • FRSX 0
  • Target Price
  • PPBT $33.00
  • FRSX N/A
  • AVG Volume (30 Days)
  • PPBT 21.8M
  • FRSX 20.5K
  • Earning Date
  • PPBT 11-14-2025
  • FRSX 11-13-2025
  • Dividend Yield
  • PPBT N/A
  • FRSX N/A
  • EPS Growth
  • PPBT N/A
  • FRSX N/A
  • EPS
  • PPBT N/A
  • FRSX N/A
  • Revenue
  • PPBT N/A
  • FRSX $452,000.00
  • Revenue This Year
  • PPBT N/A
  • FRSX N/A
  • Revenue Next Year
  • PPBT N/A
  • FRSX N/A
  • P/E Ratio
  • PPBT N/A
  • FRSX N/A
  • Revenue Growth
  • PPBT N/A
  • FRSX N/A
  • 52 Week Low
  • PPBT $0.53
  • FRSX $1.98
  • 52 Week High
  • PPBT $13.95
  • FRSX $18.41
  • Technical
  • Relative Strength Index (RSI)
  • PPBT 45.98
  • FRSX 45.61
  • Support Level
  • PPBT $0.71
  • FRSX $2.12
  • Resistance Level
  • PPBT $0.89
  • FRSX $2.33
  • Average True Range (ATR)
  • PPBT 0.13
  • FRSX 0.09
  • MACD
  • PPBT 0.01
  • FRSX -0.03
  • Stochastic Oscillator
  • PPBT 17.37
  • FRSX 12.77

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

About FRSX Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.

Share on Social Networks: